html[data-identity='g1'] .g1-header .g1-header-wide .g1-header-layers button { display: none; } html[data-identity='g1'] .g1-header-wide .g1-header-layers a { align-self: center; } html[data-identity='g1'] .g1-header .g1-header-narrow { display: none; } html[data-identity='g1'] .g1-header-nojs { display: none; } @media (width < 721px) { html[data-identity='g1'] .g1-header .g1-header-nojs { display: flex; flex-wrap: wrap; column-gap: 20px; padding: 0 16px 8px; } html[data-identity='g1'] .g1-header-nojs ul { display: flex; gap: 20px; list-style: none; margin: 0; padding: 0; box-shadow: none; } html[data-identity='g1'] .g1-header-nojs a { display: block; padding: 6px 0; font-size: 15px; line-height: 24px; color: var(--ink2); text-decoration: none; } html[data-identity='g1'] .g1-header-nojs a[aria-current='true'] { color: var(--ink); text-decoration: underline 2px var(--ember); text-underline-offset: 6px; } }

Punica granatumFinding

Punica granatum decreases interleukin‑6 concentration

lowersModerate evidenceFinding

01 · The sentence it was drawn from

“The PE resulted in a significant decrease in IL-6 levels compared to the placebo (by 5.47 ± 1.34 pg/mL (SE), p < 0.001).”

Quoted verbatim from Effects of Pomegranate Extract on Inflammatory Markers and Cardiometabolic Risk Factors in Adults Aged 55-70 Years: A Randomised Controlled Parallel Trial.

This finding among the 81 findings on its endpoint

Punica granatum

Interleukin-6 concentration

lowers

Who: Adults aged 55 to 70 years, normal weight or overweight, without diagnosed chronic disease, taking no blood-pressure, lipid or anti-inflammatory medication; control received maltodextrin placebo capsules
Dose studied: two 370 mg capsules daily (740 mg/day) for 12 weeks

Moderate evidencePMID 40218993 · 2025

02 · The study

Study: RCT
Duration: 3 months

Evidence, by strength

strong
moderatethis finding
limited
very limited
insufficient

03 · The paper

Nutrients

Effects of Pomegranate Extract on Inflammatory Markers and Cardiometabolic Risk Factors in Adults Aged 55-70 Years: A Randomised Controlled Parallel Trial.

2025PMID 40218993doi 10.3390/nu17071235

What else it reported1 finding · 0 compounds · 1 endpoint

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M71HS37WK8N0D9F2TY4AH6BW